menu
    • menu
    [{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AEVI-007","moa":"Interleukin-18","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Aevi Genomic Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Rislenemdaz","moa":"Glutamate NMDA receptor; GRIN1\/GRIN2B","graph1":"Neurology","graph2":"Phase II","graph3":"Cerecor","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Cerecor \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Cerecor"},{"orgOrder":0,"company":"Cerecor","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CERC-006","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Preclinical","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecor \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cerecor \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AEVI-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AEVI-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CERC-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CERC-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Horizon Technology Finance Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"AEVI-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Horizon Technology Finance Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Horizon Technology Finance Corporation"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AEVI-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CERC-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"AEVI-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Cerecor","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Cerecor"},{"orgOrder":0,"company":"Cerecor","sponsor":"CDG Care","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Alpha-D-Galactose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerecor \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Cerecor"}]

    Find Clinical Drug Pipeline Developments & Deals by Cerecor

    Menu

    Cerecor

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19

                            Details : CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT (tumor necrosis factor superfamily member 14, TNFSF14).

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 05, 2021

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerecor Positive Initial Phase CERC-002 in Moderate to Severe Crohn's Disease

                            Details : The study is a pilot study using a dose-escalation design to characterize the safety and tolerability of two different doses of CERC-002 (1.0 mg/kg and 3.0 mg/kg).

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 26, 2021

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEVI-007

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adu...

                            Details : CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb). IL-18 has been demonstrated to have a key role as a marker of disease activity and its concentration correlates with disease severity in AOSD patients.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 05, 2021

                            Lead Product(s) : AEVI-007

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CERC-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerecor Announces Successful Proof of Concept Data for CERC-002

                            Details : COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in the primary endpoint (proportion of patients alive and free of respiratory failure over the 28-day study period) compared ...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 01, 2021

                            Lead Product(s) : CERC-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002

                            Details : CERC-002 is a first-in-class anti-LIGHT monoclonal antibody. LIGHT is homologous to lymphotoxin and exhibits an inducible expression. It competes with the HSV glycoprotein D for binding to the herpesvirus entry mediator, a receptor expressed on T lymphoc...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 29, 2021

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Horizon Technology Finance Corporation

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology F...

                            Details : This second tranche is in connection with the Company’s successful positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully human anti-LIGHT monoclonal antibody for moderate- to-severe...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 08, 2021

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Horizon Technology Finance Corporation

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alpha-D-Galactose

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : CDG Care

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CD...

                            Details : This trial will study the safety, tolerability, and efficacy of CERC-801 in patients with PGM1-CDG using daily therapeutic doses of CERC-801 in approximately ten patients.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 17, 2020

                            Lead Product(s) : Alpha-D-Galactose

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : CDG Care

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CERC-002

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Dise...

                            Details : Cerecor has resumed the Phase 1b clinical study of CERC-002 in anti-TNF refractory adult Crohn’s patients with the lifting of the moratorium on elective endoscopy resulting from the COVID-19 pandemic.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            August 26, 2020

                            Lead Product(s) : CERC-002

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CERC-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVI...

                            Details : Publication supports Cerecor clinical program evaluating CERC-002, the only clinical stage anti-LIGHT monoclonal antibody, as a potential treatment for patients with severe COVID-19 acute respiratory distress syndrome.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            August 13, 2020

                            Lead Product(s) : CERC-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Cerecor

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS

                            Details : U.S. Food and Drug Administration has given clearance to proceed with a proof-of-concept clinical trial of Cerecor's anti-LIGHT monoclonal antibody CERC-002 in patients with COVID-19 cytokine storm induced Acute Respiratory Distress Syndrome (ARDS).

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 28, 2020

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth